ライフサイエンスコーパス: serum magnesium

1 ry (EA) populations identified nine loci for serum magnesium.

2 xtend our understanding of the metabolism of serum magnesium.

3 ificantly correlated with increased level of serum magnesium.

4 Low serum magnesium and high serum phosphorus and calcium we

5 ession models to assess associations between serum magnesium and radiographic subarachnoid hemorrhage

6 of HF is greater among individuals with low serum magnesium and those with high serum phosphorus and

7 Elevated levels of serum magnesium are associated with lower risk of cardio

8 analysis to examine the association between serum magnesium at baseline and risk of incident AF.

9 Serum magnesium, bicarbonate, albumin, and phosphate lev

10 owed a statistically significant increase in serum magnesium concentration at 6 hrs when compared wit

11 ficant trends in fracture risk in men across serum magnesium concentration groups were apparent for s

12 together explained 2.8 % of the variance in serum magnesium concentration in ARIC African-American p

13 loci that explained 2.8% of the variance in serum magnesium concentration in ARIC African-American p

14 se and MUC1 and between insulin and TRPM6 on serum magnesium concentration in ARIC European-American

15 m-glucose cotransporter 2 inhibitors elevate serum magnesium concentration in patients with or withou

16 The change in serum magnesium concentration was greater in women consu

17 gated associations of BUA and fractures with serum magnesium concentration.

18 onic Health Evaluation II scores, or initial serum magnesium concentration.

19 75-675/> 675 ng/gHb respectively) (99%), low serum magnesium concentrations (< 0.75 mmol/L) (59%), an

20 In contrast, 5 patients (14%) had low serum magnesium concentrations (< 0.75 mmol/L).

21 yte magnesium concentrations correlated with serum magnesium concentrations (r(s) = 0.338, p < 0.05)

22 001) and basal ETKA (p < 0.05) increased and serum magnesium concentrations decreased (p < 0.001).

23 ole blood TDP and basal ETKA increased while serum magnesium concentrations decreased, indicating inc

24 Serum magnesium concentrations did not differ after 12 w

25 um potassium concentrations of 3.5 mmol/L or serum magnesium concentrations of < 1.8 mg/dL (< 0.74 mm

26 On day1 serum magnesium concentrations were directly associated

27 ine magnesium concentrations, the changes in serum magnesium concentrations were not significantly di

28 Post-operatively 14 patients (40%) had low serum magnesium concentrations.

29 mmon practice in critical care to supplement serum magnesium for the purpose of preventing episodes o

30 Low serum magnesium has been linked to increased risk of atr

31 The regulation of serum magnesium homeostasis is not well understood.

32 We conducted a GWAS of serum magnesium in 2737 AA participants of the Atheroscl

33 i have been reported involving regulation of serum magnesium in adults.

34 ere to identify genetic loci associated with serum magnesium in an African-American (AA) population u

35 educes kidney magnesium wasting and restores serum magnesium in cisplatin-treated rats, likely throug

36 licated in a dataset from a previous GWAS of serum magnesium in European adults.

37 duals within NIPAL1 families suggested lower serum magnesium in NPC compared to unaffected members.

38 In addition, lower serum magnesium is associated with higher risk of cardio

39 Low serum magnesium is moderately associated with the develo

40 highest frequency rate (72%) and lowest mean serum magnesium level (0.66 +/- 0.17 mmol/L) in patients

41 wed an inverse relationship between baseline serum magnesium level and NODAT (hazard ratio [HR], 1.24

42 31, 2011, to examine the association between serum magnesium level and NODAT.

43 r results suggest that lower post-transplant serum magnesium level is an independent risk factor for

44 count, platelet count, serum albumin level, serum magnesium level, and cisplatin dose.

45 te to severe shivering (p = 0.04), and lower serum magnesium levels (p = 0.01) were associated with g

46 f rs17251221 was also associated with higher serum magnesium levels (P = 1.2 * 10(-3)), lower serum p

47 SGLT2i increased serum magnesium levels and reduced uric acid levels.

48 We tested the hypothesis that admission serum magnesium levels are associated with extent of hem

49 Previous genetic studies indicate that serum magnesium levels are highly heritable, and a few g

50 Low serum magnesium levels could be associated with increase

51 Low serum magnesium levels have been associated with multipl

52 dy, we examined if additional loci influence serum magnesium levels in children.

53 iosis and craniofacial anomalies should have serum magnesium levels monitored closely after surgery.

54 ate ratios of ischemic stroke for those with serum magnesium levels of <or=1.5, 1.6, 1.7, and >or=1.8

55 Future studies are needed to test whether serum magnesium levels predict risk of HF.

56 A significant reduction in serum magnesium levels was observed among sporadic NPC c

57 Higher serum magnesium levels were associated with lower preval

58 Clinically, low serum magnesium levels were associated with more rapid d

59 Furthermore, in PRL-2 knockout mice, serum magnesium levels were significantly elevated as co

60 an for 3 months moving at 3-month intervals) serum magnesium levels while adjusting for potential con

61 and apparent recessive effects of C1QTNF8 on serum magnesium levels.

62 actional excretion of magnesium and restored serum magnesium levels.

63 participants, GDs were associated with lower serum magnesium, lower educational achievement, and high

64 Hypomagnesemia (serum magnesium <0.74 mmol/L) also significantly associa

65 Hypomagnesemia (defined as total serum magnesium <0.75 mmol/L) was found in 51 (11%) of t

66 nterval, 6.7-11.9) in the lowest quartile of serum magnesium (</=1.77 mg/dL) compared with 6.3 per 10

67 Low serum magnesium (Mg) concentrations have been associated

68 Low serum magnesium (Mg) levels are associated with an incre

69 on (P>0.11 for all biomarkers), whereas both serum magnesium (P<0.001) and uric acid levels (P=0.008)

70 4142110 was correlated with higher levels of serum magnesium, phosphorus, and lower AKP level.

71 Magnesium doses were targeted to achieve serum magnesium ranges of 1.0-1.85 mmol/L or 1.25-2.5 mm

72 further work is required to identify optimal serum magnesium targets for atrial fibrillation prophyla

73 ntensive care unit (ICU) patients undergoing serum magnesium testing was conducted in 93 ICUs across

74 Restoring the concentrations of serum magnesium to normal values by high-dose magnesium

75 Interventions targeting serum magnesium to reduce the risk of NODAT should be ev

76 with beneficial effects for individuals with serum magnesium values close to those cutoffs.

77 correlate with hypomagnesemia and to predict serum magnesium values in critically ill pediatric patie

78 Total serum magnesium values were obtained within the first 24

79 Mean serum magnesium was 1.88 mg/dL.

80 However, serum magnesium was in the upper normal to hypermagnesem

81 Serum magnesium was inversely associated with ischemic s

82 Serum magnesium was significantly negatively associated

83 heart disease, impaired renal function, and serum magnesium, was identified as an independent risk f

84 odels, individuals in the lowest quartile of serum magnesium were ~50% more likely to develop AF (adj

85 e kidney plays a central role in maintaining serum magnesium within a narrow range (0.70-1.10 mmol/L)